James Machek - Endologix Vice President - Research and Development
President
Mr. James E. Machek serves as Vice President Research and Development, Manufacturing, Irvine of Endologix, Inc. Mr. Macheck joined us in April 2013 as our Vice President, Research Development, Nellix Technologies, and was promoted to Vice President, Research and Development on July 15, 2013. Mr. Machek assumed responsibility for our manufacturing operations at our Irvine facility following our merger with TriVascular in February 2016. Mr. Machek has more than 20 years of experience in the medical device industry, including bringing new products from development through commercialization. Prior to joining us, Mr. Machek served as Senior Director of Program Management for the Surgical Solutions business segment of Covidien, which was spun out of Tyco Healthcare in June 2007. Mr. Machek also held the position of Director of Global Development Engineering and Program Management at Tyco Healthcare. Prior to this, he was Senior Director of Product Development at St. Jude Medical, Inc. From 1999 to 2009, Mr. Machek held roles of increasing responsibility in the Endovascular Solutions business segment at Medtronic, Inc., including Senior Director of Research and Development and Portfolio Management and Director of Operations, Endovascular Stent Grafts. His medical device experience also includes positions at Sulzer Intermedics, Schneider USA and Medrad since 2015.
| Age | 58 |
| Tenure | 9 years |
| Phone | 949 595-7200 |
| Web | http://endologix.com |
Endologix Management Efficiency
The company has return on total asset (ROA) of (9.82) % which means that it has lost $9.82 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (167.38) %, meaning that it created substantial loss on money invested by shareholders. Endologix's management efficiency ratios could be used to measure how well Endologix manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 195.94 M in liabilities with Debt to Equity (D/E) ratio of 3.67, implying the company greatly relies on financing operations through barrowing. Endologix has a current ratio of 0.38, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Endologix until it has trouble settling it off, either with new capital or with free cash flow. So, Endologix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Endologix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Endologix to invest in growth at high rates of return. When we think about Endologix's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Stacey Goodman | Federal Home Loan | 55 | |
| John Krenitsky | Federal Home Loan | N/A | |
| Carol Wambeke | Federal Home Loan | 54 | |
| Timothy Kitt | Federal Home Loan | N/A | |
| Ricardo Anzaldua | Federal Home Loan | 64 | |
| Timothy Boswell | Willscot Mobile Mini | 45 | |
| Dwight Robinson | Federal Home Loan | 60 | |
| Dale Asplund | United Rentals | 56 | |
| Craig Pintoff | United Rentals | 54 | |
| Timothy Kenny | Federal Home Loan | 52 | |
| Chris Hummel | United Rentals | N/A | |
| Mark DeLong | Federal Home Loan | 60 | |
| Eli Baker | Willscot Mobile Mini | 39 | |
| Hezron Lopez | Willscot Mobile Mini | 53 | |
| Philip Scruggs | AerCap Holdings NV | 54 | |
| Paul McDonnell | United Rentals | 53 | |
| Jessica Graziano | United Rentals | 47 | |
| Donald Kish | Federal Home Loan | 48 | |
| Robert Lux | Federal Home Loan | 52 | |
| David Brickman | Federal Home Loan | 52 | |
| Ted Grace | United Rentals | N/A | |
Management Performance
| Return On Equity | -167.38 | |||
| Return On Asset | -9.82 |
Endologix Leadership Team
Elected by the shareholders, the Endologix's board of directors comprises two types of representatives: Endologix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endologix. The board's role is to monitor Endologix's management team and ensure that shareholders' interests are well served. Endologix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endologix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Chavez, Director | ||
| Greg Morrow, Chief Marketing Officer | ||
| John McDermott, Chairman of the Board, CEO | ||
| Patrick Stephens, Vice President - Research and Development | ||
| Leslie Norwalk, Director | ||
| Matthew Thompson, Chief Medical Officer | ||
| Gregory Waller, Independent Director | ||
| Jeffrey Stelk, Vice President - U.S. Sales | ||
| Guido Neels, Independent Director | ||
| Joseph DeJohn, Vice President - Sales | ||
| Michael Maszy, Vice President - Manufacturing | ||
| Shari OQuinn, Vice President - Regulatory and Quality Affairs | ||
| Charles Love, Vice President - Clinical Affairs | ||
| Janet Fauls, Director - Regulatory Affairs | ||
| John Onopchenko, COO | ||
| James Machek, Vice President - Research and Development | ||
| David Jennings, VP of HR | ||
| Vaseem Mahboob, CFO | ||
| Thomas Zenty, Independent Director | ||
| Amanda DePalma, VP of Global Marketing | ||
| Jose Lima, VP of Quality | ||
| Cecille Ferracci, General Manager - Europe | ||
| Jeff Fecho, Chief Quality Officer | ||
| Todd Abraham, Vice President - Operations | ||
| Michael Chobotov, CTO | ||
| Meredith Huetter, Vice President - Global Medical Affairs | ||
| Thomas Wilder, Independent Director | ||
| Daniel Lemaitre, Lead Independent Director | ||
| Robert Mitchell, President | ||
| Laura Nagel, Vice President - Global Quality | ||
| Jeremy Hayden, General Counsel, Corporate Secretary |
Endologix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endologix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -167.38 | |||
| Return On Asset | -9.82 | |||
| Profit Margin | (44.65) % | |||
| Operating Margin | (33.99) % | |||
| Current Valuation | 159.27 M | |||
| Shares Outstanding | 19.17 M | |||
| Shares Owned By Insiders | 4.69 % | |||
| Shares Owned By Institutions | 74.71 % | |||
| Number Of Shares Shorted | 343.57 K | |||
| Price To Earning | (5.55) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Endologix in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Endologix's short interest history, or implied volatility extrapolated from Endologix options trading.
Pair Trading with Endologix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endologix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endologix will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to American Electric could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace American Electric when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back American Electric - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling American Electric Power to buy it.
The correlation of American Electric is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as American Electric moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if American Electric Power moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for American Electric can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Endologix information on this page should be used as a complementary analysis to other Endologix's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Endologix Stock
If you are still planning to invest in Endologix check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Endologix's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |